JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan notes that while there's a resurgence of interest and excitement in new product launches within the specialty group, including branded and complex generics/biosimilars, investors should be discerning about these opportunities.
JP Morgan指出，儘管專業團隊內的新產品推出引起了興趣和激動，包括品牌和複雜仿製藥/生物相似物，但投資者應該對這些機會保持警惕。
The group's core fundamentals have strengthened, buoyed by a more stable environment for generic and established brand pricing, which helps mitigate the usual erosion in base business prices.
該團隊的核心基本面已經加強，得益於對於普通仿製藥和成熟品牌定價更穩定的環境，這有助於減輕基本業務價格的常規衰減。
However, growth in the overall sector remains modest, with most companies experiencing a top-line compound annual growth rate (CAGR) of 0-2%.
然而，整個行業的增長仍然溫和，大多數公司的銷售額複合年增長率（CAGR）爲0-2%。
Additionally, valuations have recovered, with most stocks now trading near their historical averages.
此外，估值已經回升，大多數股票現在交易價格接近其歷史平均水平。
JP Morgan writes that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) continues to be the primary focus among investors in the group, with sentiment growing more bullish.
JP Morgan表示，梯瓦製藥繼續是該團隊投資者的主要關注點，市場情緒變得更加看好。
The analyst maintains a Neutral rating, as the market seems to have fully accounted for the company's branded pipeline. Additionally, JP Morgan is cautious about Teva's U.S. generic business compared to market expectations.
分析師維持中立評級，因爲市場似乎已經充分考慮到了該公司的品牌產品線。此外，JP Morgan對梯瓦的美國仿製藥業務持謹慎態度，與市場預期相比。
The analyst has given Viatris Inc. (NASDAQ:VTRS) a Neutral rating, citing its stable fundamentals and low valuation amidst uncertainties in business development.
分析師對Viatris Inc.（NASDAQ:VTRS）給予中立評級，指出其穩定的基本面和低估值，儘管業務發展存在不確定性。
Meanwhile, JP Morgan holds a more optimistic view, an Overweight rating on Perrigo Co plc (NYSE:PRGO), noting the potential for earnings per share (EPS) to rebound to the low-mid $3 range soon due to currently low market sentiment. With shares currently trading at a significantly lower price than other consumer sector peers, the analyst believes there is substantial potential for an increase in valuation multiples as the recovery progresses.
同時，JP Morgan對Perrigo Co plc（NYSE:PRGO）持更樂觀的看法，給予增持評級，指出由於目前市場情緒較低，每股收益（EPS）有望回升至3美元低中區間。分析師認爲，目前股價較其他消費領域同行股票交易價格顯着較低，隨着復甦的進行，估值倍數增加的潛力很大。
Similarly, positive prospects are seen for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), where the analyst anticipates a promising series of catalysts leading into 2024/2025. Keeps Overweight rating.
同樣，分析師預計Amphastar Pharmaceuticals, Inc. (納斯達克:AMPH)展望積極，預計2024/2025年期間將迎來一系列有利的催化劑。給予超重評級。
JP Morgan is adjusting several ratings, which are relative to each other. The analyst has changed Amneal Pharmaceuticals, Inc (NASDAQ:AMRX) to Neutral from Underweight and Organon & Co (NYSE:OGN) to Underweight from Neutral.
JP Morgan正在調整若干評級，這些評級之間相對比較。分析師將Amneal Pharmaceuticals, Inc (納斯達克:AMRX)從空頭調整爲中立，將Organon & Co (紐交所:OGN)從中立調整爲空頭。
For Amneal, the company's success in launching new products suggests the potential for improved financial forecasts, which could bolster the stock.
對於Amneal，公司在推出新產品方面的成功表明其財務預測有改善的潛力，這可能提振股票價格。
Conversely, Organon's stock price has increased 60% year-to-date. Although its valuation still appears low, the recent price surge suggests more attractive opportunities within the sector may exist.
相反，Organon的股票價格今年迄今已上漲60%。儘管估值仍然較低，但最近的價格飆升表明該行業內可能存在更有吸引力的機會。
Price Action: OGN stock is down 2.95% at $20.73, and AMRX stock is down 1.42% at $8.33 at last check Friday.
價格變動：OGN股價最新一次檢查時下跌2.95%，爲$20.73，AMRX股價最新一次檢查時下跌1.42%，爲$8.33。
Photo via Shutterstock
圖片來自shutterstock。
- Robinhood Shifted From Meme Stock To Market Contender Amid New Products And Global Expansion: Analyst Upgrades Stock.
- 羅賓漢由熱門股票轉變爲市場競爭對手，推出新產品和全球擴張：分析師將股票評級提升。
譯文內容由第三人軟體翻譯。